| Product Name |
Lentivirus Pseudotyped with SARS-CoV-2 Spike Glycoprotein, HexaPro Stabilized Trimer |
| Description |
Lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein, with hexaPro mutations so the surface protein antigenically optimal pre-fusion conformation, produced and purified from HEK 293 cells |
| Mutations |
Furin site RRAR mutated to GSAS; HexaPro mutations (K986P, V987P, F817P, A892P, A899P and A942P) to ensure the S glycoprotein remains in an antigenically optimal pre-fusion conformation |
| Source |
HEK293T cells |
| Reporter |
EGFP |
| Application |
- Screening of SARS-CoV-2 neutralizing antibodies
- Assessment of vaccine efficacy
|
| Titer |
> 1 X 107 RFU/ml or > 1 X 105 TU/ml |
| Shipping |
Dry ice |
| Storage |
-80 oC |
| References |
-
- Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein. Sci Rep 10, 19076 (2020). doi:10.1038/s41598-020-76135-w
- Prospective Mapping of Viral Mutations that Escape Antibodies Used to Treat COVID-19. Science. 371 (2020): 850-854. doi: 10.1126/science.abf9302. PubMed: 33495308.
|